Drug Search Results
More Filters [+]

Ticagrelor

Alternative Names: ticagrelor, brilinta, brilique, azd6140
Latest Update: 2024-09-27
Latest Update Note: Clinical Trial Update

Product Description

Ticagrelor (Brilique™, Brilinta®), a cyclopentyl-triazolopyrimidine, is an orally active, reversible, and selective adenosine diphosphate (ADP) receptor antagonist indicated for use in patients with acute coronary syndromes (ACS). Ticagrelor has a faster onset of action and provides greater inhibition of platelet aggregation than clopidogrel.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25672642/)

Mechanisms of Action: P2Y12 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Acute Coronary Syndrome | Coronary Artery Disease | Coronary Disease | Coronary Thrombosis | Myocardial Infarction | Thrombosis | Ischemic Stroke | Ischemic Attack, Transient | Stroke | General Diabetes | Type 2 Diabetes

Known Adverse Events: Dyspnea | Injuries/wounds Unspecified

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ticagrelor

Countries in Clinic: Australia, Belgium, Canada, China, Colombia, Croatia, Germany, Hungary, India, Ireland, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Spain, United Kingdom, United States

Active Clinical Trial Count: 14

Highest Development Phases

Phase 3: COVID-19|Coronary Artery Disease|Influenza, Human|Myocardial Infarction|Pneumonia|Thrombosis

Phase 2: Atherosclerosis|Carotid Artery Thrombosis|Carotid Stenosis|Coronary Stenosis|Coronary Thrombosis|Myocardial Ischemia

Phase 1: Acute Coronary Syndrome|Healthy Volunteers|Oncology Solid Tumor Unspecified|Stroke

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2023-507015-35-00

P3

Not yet recruiting

Coronary Artery Disease

2029-07-30

ANGIODAPT

P3

Active, not recruiting

Coronary Artery Disease

2029-07-21

REMAP-CAP

P3

Recruiting

Pneumonia|Influenza, Human|COVID-19

2026-02-01

TADCLOT

P3

Recruiting

Thrombosis|Myocardial Infarction

2024-11-15

Recent News Events